Alexza Pharmaceuti Com Usd0.000 (NASDAQ:ALXA)

Alexza Pharmaceuticals, Inc. (Alexza), incorporated on December 19, 2000, is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. As of December 31, 2010, the Company had screened more than 400 drug compounds and identified approximately 200 drug compounds that demonstrate initial vaporization. As of December 31, 2010, Alexza’s product candidates in active development were AZ-004 (Staccato loxapine), AZ-007 (Staccato zaleplon) and Staccato nicotine. As of December 31, 2010, its products candidates not in active development are AZ-104 (Staccato loxapine, low-dose), AZ-002 (Staccato alprazolam) and AZ-003 (Staccato fentanyl).

Web site: http://www.alexza.com/

Last updated July 30, 2012